Biopreservation Market Size and Forecast 2026–2034

Global Biopreservation Market Outlook

The global biopreservation market is entering a transformative growth phase as healthcare systems, research institutions, and biotechnology companies increasingly depend on long-term preservation of biological materials. According to Renub Research, the biopreservation market is expected to reach US$ 22.76 billion by 2034, rising from US$ 9.62 billion in 2025, expanding at a robust CAGR of 10.04% from 2026 to 2034.

Download Free Sample Report

This rapid growth reflects the rising importance of regenerative medicine, stem cell therapy, gene therapy, and personalized medicine, all of which rely heavily on the availability of viable, high-quality biological samples. At the same time, expanding biobanking initiatives, increasing R&D investments, and technological advances in cryogenic storage systems are accelerating market adoption across healthcare, pharmaceutical, and life science sectors worldwide.

As the world moves toward precision healthcare and cell-based therapies, biopreservation is no longer a support function—it has become a strategic pillar of modern medicine.

Biopreservation Industry Overview

Biopreservation refers to the process of maintaining the structural integrity, viability, and functionality of biological samples for extended periods. These samples may include cells, tissues, organs, DNA, RNA, vaccines, and other biologics used in research, diagnostics, and clinical applications.

To achieve this, biopreservation relies on a range of advanced techniques such as:

Cryopreservation

Vitrification

Hypothermic storage

Freeze-drying (lyophilization)

These methods prevent biological degradation while allowing materials to be safely stored, transported, and reused when needed. Biopreservation plays a vital role in biobanking, drug discovery, regenerative medicine, vaccine development, and cell therapy manufacturing, ensuring that samples remain viable from the laboratory to the clinic.

With the global healthcare industry increasingly focused on long-term disease management and personalized therapies, the demand for reliable, scalable, and compliant biopreservation solutions continues to grow.

Key Growth Drivers of the Biopreservation Market

1. Expansion of Regenerative Medicine and Cell Therapy

The rapid expansion of regenerative medicine is one of the most powerful drivers of the biopreservation market. Stem cell therapy, gene therapy, and tissue engineering require carefully preserved biological materials to maintain their therapeutic potential.

As the number of cell and gene therapy clinical trials increases worldwide, the need for advanced cryogenic storage, controlled-rate freezing systems, and reliable cold-chain logistics has surged. Biopreservation ensures that cells and tissues retain their functionality throughout the research, manufacturing, and treatment process.

Additionally, the global rise in chronic diseases such as cancer, diabetes, autoimmune disorders, and cardiovascular conditions is driving demand for regenerative solutions. Government funding, academic research programs, and private investments are rapidly expanding infrastructure for cell-based science, directly boosting biopreservation technology adoption.

2. Growth of Biobanking and Precision Medicine

Biobanking has become a cornerstone of modern biomedical research. Large-scale biobanks store millions of biological samples that enable scientists to study disease mechanisms, genetic variations, and drug responses.

The shift toward precision medicine—where treatments are tailored to individual genetic and molecular profiles—has intensified the need for high-quality, long-term sample preservation. Biopreservation systems ensure sample consistency, viability, and traceability, which are essential for generating reliable clinical and genomic insights.

Furthermore, the integration of automation, digital tracking, and AI-powered laboratory information management systems (LIMS) is transforming biobanks into highly efficient, data-driven ecosystems. Public–private collaborations and government-backed population health studies continue to expand global biobanking capacity, fueling sustained market growth.

3. Technological Advancements in Preservation and Storage Solutions

Continuous innovation in preservation technologies is accelerating the biopreservation market’s expansion. Advances in non-toxic cryoprotectants, vitrification protocols, controlled-rate freezing, and automated monitoring systems have significantly improved post-thaw cell viability and storage reliability.

A notable milestone came in March 2025, when Teknova and Pluristyx launched PluriFreeze™, an integrated cryopreservation system designed to improve cell therapy viability while reducing development timelines. This solution simplifies freezing workflows and enhances recovery rates, supporting more efficient cell and gene therapy manufacturing.

Meanwhile, innovations in ultra-low-temperature freezers, smart sensors, and high-density automated storage systems are helping laboratories meet strict regulatory requirements while reducing human error. These technologies are now essential for biologics manufacturing, vaccine development, stem cell banking, and advanced diagnostics.

Challenges Facing the Biopreservation Market

High Cost of Equipment and Infrastructure

Despite strong growth, the biopreservation market faces challenges, particularly the high cost of advanced storage equipment and infrastructure. Cryogenic freezers, liquid nitrogen systems, and cold-chain logistics require substantial capital investment, limiting accessibility for smaller laboratories and emerging markets.

In addition to upfront costs, ongoing expenses related to energy consumption, maintenance, regulatory validation, and monitoring systems add financial pressure. As biobanking and cell therapy volumes grow, the industry must focus on scalable, cost-efficient preservation solutions to ensure broader global adoption.

Stringent Regulatory Requirements and Quality Control

Biopreservation involves storing materials intended for research, diagnostics, and human therapy, making regulatory compliance essential. Strict guidelines govern sample handling, storage conditions, cryoprotectant use, and equipment validation, requiring extensive documentation and quality assurance.

Global differences in regulatory frameworks add complexity for multinational biobanks and pharmaceutical companies. Ensuring consistent quality across multiple facilities remains a major operational challenge, especially as sample volumes grow. These regulatory demands can slow market expansion but also drive innovation in automated monitoring and compliance-focused storage solutions.

Regional Market Insights

United States Biopreservation Market

The United States leads the global biopreservation market, supported by a strong biotechnology ecosystem, advanced healthcare infrastructure, and high investment in regenerative medicine. The country hosts numerous biobanks, cell therapy manufacturers, and research institutions that rely on advanced cryogenic storage solutions.

Government funding, robust clinical trial activity, and the presence of major industry players accelerate innovation and adoption. With a growing burden of chronic diseases and expanding precision medicine initiatives, the U.S. market is expected to maintain its leadership position throughout the forecast period.

Germany Biopreservation Market

Germany stands as a major European hub for biopreservation, driven by its strong biomedical research ecosystem and advanced engineering capabilities. The country invests heavily in stem cell research, personalized medicine, and biobanking programs, fueling demand for high-quality preservation systems.

Germany’s strict regulatory standards promote adoption of technologically advanced, compliant storage solutions, while collaborations between pharmaceutical companies and research institutes drive continuous innovation. The country remains a key contributor to Europe’s biopreservation landscape.

China Biopreservation Market

China’s biopreservation market is expanding rapidly, supported by government investment in biotechnology, population health studies, and regenerative medicine. The country is seeing significant growth in stem cell research, gene therapy development, and biopharmaceutical manufacturing, all of which require advanced preservation solutions.

Large-scale precision medicine programs and the rise of domestic biotech companies continue to strengthen market demand. Although regulatory systems are still evolving, improvements in quality standards and infrastructure position China for long-term growth.

Saudi Arabia Biopreservation Market

Saudi Arabia’s biopreservation market is gaining momentum under Vision 2030, which prioritizes healthcare innovation and biotechnology development. Investments in medical research centers, biobanks, and genomic programs are increasing the need for cryogenic storage and preservation media.

While the market remains smaller than Western counterparts, strong government support, infrastructure development, and rising interest in personalized medicine are accelerating adoption. Long-term health initiatives position Saudi Arabia as an emerging biopreservation market in the Middle East.

Recent Developments in the Biopreservation Market

May 2025: Azenta Inc. partnered with Form Bio to develop an integrated sequencing and AI-driven data analysis platform for AAV gene therapy development.

March 2025: Johnson & Johnson announced plans to invest over USD 55 billion in U.S. operations, including new manufacturing facilities requiring advanced biopreservation systems.

February 2025: Thermo Fisher Scientific launched the Krios 5 Cryo-TEM, featuring AI-powered automation for atomic-resolution imaging in structural biology.

January 2025: Azenta Inc. was selected by the UK Biocentre to deploy its BioArc Ultra automated storage system, expanding capacity by ~16 million samples.

June 2023: BioLife Solutions introduced a new large-capacity controlled-rate freezer to support high-volume cell therapy manufacturing.

January 2023: Thermo Fisher Scientific completed its acquisition of The Binding Site Group, strengthening its specialty diagnostics portfolio.

Market Segmentation

By Product

Equipment

Media

Laboratory Information Management System (LIMS)

By Application

Regenerative Medicine

Biobanking

Drug Discovery

By Geography

North America: United States, Canada

Europe: France, Germany, Italy, Spain, United Kingdom, Belgium, Netherlands, Turkey

Asia Pacific: China, Japan, India, South Korea, Thailand, Malaysia, Indonesia, Australia, New Zealand

Latin America: Brazil, Mexico, Argentina

Middle East & Africa: Saudi Arabia, UAE, South Africa

Key Players in the Global Biopreservation Market

Thermo Fisher Scientific Inc.

Cryoport, Inc.

Eppendorf AG

BioLife Solutions Inc.

Azenta Inc.

Merck KGaA

Qiagen NV

Chart Industries, Inc.

Each company is analyzed across five viewpoints: business overview, key leadership, recent strategies, SWOT analysis, and financial insights.

Final Thoughts

The biopreservation market is evolving from a supportive laboratory function into a core enabler of next-generation healthcare. With regenerative medicine, cell therapy, and precision medicine becoming central to modern treatment models, the ability to preserve biological materials safely and efficiently is more critical than ever.

Driven by technological innovation, expanding biobanks, and increasing global investment in life sciences, the market is poised for strong, sustained growth through 2034. As regulatory frameworks mature and cost-efficient technologies emerge, biopreservation will play a defining role in shaping the future of medicine, research, and global health innovation.